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ABSTRACT 
 
MicroRNAs (miRNAs) are short non-coding RNA molecules (18‒25 nucleotides) well-
known for their post-transcriptional gene regulatory roles. The pathophysiology of various dis-
eases (such as neurodegenerative, cardiovascular, etc.) and in particular cancer, have been char-
acterised by the abnormal cellular expression levels of miRNAs. Therefore, validation and clini-
cal implementation of reliable miRNA-based biomarkers would be appreciably helpful. To uti-
lize miRNA potential in disease diagnosis and prognosis, accurate and robust quantitative ap-
proaches are required to analyze the sets of deregulated miRNAs (particular to a certain disease) 
in minimally-processed clinical samples. One such technique, developed by our lab, is direct 
quantitative analysis of multiple miRNA (DQAMmiR) using commercial capillary electrophore-
sis (CE) setting. The hybridization-based method is direct; does not require any miRNA pro-
cessing or extraction, and just uses fluorescently labeled single stranded (ss) DNA probes and 
two kinds of mobility shifters: (i) single-stranded binding protein  (SSB) in CE run buffer (binds 
to the excess probes and facilitate their separation from the hybrids), (ii) different length peptide 
drag tags conjugated to the ssDNA probes (render different charge: size ratios amongst the hy-
brids and enable their separation from each other); to simultaneously detect, separate and quanti-
fy multiple miRNAs. In my study, we introduced and developed a second-generation of 
DQAMmiR, which is simpler than the first-generation, as it omits the addition of SSB in CE run 
buffer by the use of uncharged Peptide Nucleic Acid (PNA) instead of ssDNA as the hybridiza-
tion probes. The logistics behind incorporating PNA in our assay were derived based on the fol-
lowing considerations: PNA itself has no charge while the formed PNA‒miRNA hybrids would 
possess partial negative charge (from miRNAs); this difference in charges should be sufficient to 
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resolve the excess of unbound PNA probes from the formed PNA‒miRNA hybrids. Yet, the pep-
tide drag tags would be required in order to separate the hybrids from each other. In proof-of-
principle, the initial study was performed on a single miRNA to examine separation of the excess 
probe and formed hybrid. This was followed by the quantitative analysis of multiple miRNAs 
using complementary PNA/PNA-peptide probes. Overall, the assay proved to be accurate and 
precise for the analysis of three miRNAs, simultaneously. Ultimately, the performance of the as-
say was validated in presence of prostate cancer (PCa)-derived crude cell lysate for the analysis 
of two PCa-specific dysregulated miRNAs. The obtained results were found accurate, precise 
and robust, irrespective of sample matrix, even at low detection limits. With ongoing improve-
ments, PNA-facilitated DQAMmiR is rapidly getting closer to its diagnostic applications in the 
clinical setups. 
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Chapter One 
INTRODUCTION 
 
1.1 Biomarkers 
The application of biomarkers in diagnosis and management of large number of diseases, 
such as cardiovascular disorders, infections, immunological and genetic disorders and, cancer in 
particular, is well-known [1]. Biomarkers can be defined as; 
  “a characteristic that is objectively measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes, or pharmacologic responses to a therapeutic interven-
tion” 
Diagnostic biomarkers are used to critically detect or confirm the presence of a disease 
or a condition of interest or to identify individuals with a subtype of the disease. The strengthen-
ing of the robustness of discovery technologies, particularly in genomics, proteomics and metab-
olomics, has been followed by intense discussions on establishing well-defined evaluation pro-
cedures for the identified biomarkers to ultimately allow their clinical validation and implemen-
tation. The importance of accurate diagnosis warrants the assessment of the clinical performance 
of diagnostic biomarkers [2]. The stages involved in biomarker development are shown in Fig-
ure 1.  
 
- National Institutes of Health Biomarkers Definition Working Group, 1998 
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Figure 1: Stages in biomarker development involves multiple steps, linking initial discovery in basic 
studies, assay development and clinical validation and implementation. However, the validation and assay 
development (red box) is the rate-limiting step which is evident by low estimated rate (0.1%) of the suc-
cessful clinical implementation of biomarkers [3]. 
 
The ideal diagnostic biomarker test should have 100% sensitivity (i.e., correct identifica-
tion of the fraction of people with disease who test positive) and 100% specificity (i.e., correct 
identification of the fraction of people without the disease who test negative) [4]. However, the 
search of scientific literature clearly indicates that most of the published biomarkers are chal-
lenged either by the clinical sensitivity, specificity or more particularly, the robustness of the an-
alytical techniques; therefore, inadequate to replace the existing clinical tests or only useful for 
detecting advanced disease stage, where the survival rate is low [5]. 
Nevertheless, in the view of urgent need for decent disease prognosis and treatment, 
which will positively impact the morbidity and mortality, the biomarker field is now moving 
more quickly towards clinical translation [6, 7] and significant research is now projected towards 
the identification of sound biomarkers,  critical selection of analytical technique and develop-
ment of the robust, accurate, sensitive, free of biases and cost-effective assays in practice.  
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1.2 Introduction to microRNA 
The small non-coding RNAs families, such as 21‒22 nucleotides short interfering RNAs 
(siRNAs), 26‒30 nucleotides PIWI-associated RNA (piRNAs), 18‒24 nucleotides microRNAs 
(miRNAs), and others; are well-known to perform multiple cell regulatory functions. However, 
miRNAs, in particular, is the most thoroughly investigated class due to their participation in up 
to 50% of the total gene regulatory events. MicroRNAs (miRNAs) function post transcriptionally 
by the interaction with 3-untranlated region (3’-UTR) of the coding mRNAs, to inhibit transla-
tion with or without degradation of the mRNA transcripts. They are evolutionary conserved and  
involved in the determination of cell fate and pattern formation in embryonic development and, 
control of cell proliferation, cell differentiation and cell death [8]. In addition, miRNAs have 
demonstrated a strong correlation with disease progression in cancer, cardiovascular disorders, 
neurodegeneration, and numerous other pathologies [9].   
1.2.1 MiRNAs Biogenesis 
Originally, discovered in Caenorhabditis elegans in the beginning of 1990s [10], the bio-
genesis of miRNAs takes place through multiple steps under tight temporal and spatial control 
(as shown in Figure 2). Following the transcription by RNA polymerase II, Drosha processes the 
primary miRNA transcript (pri-miRNA) into 60‒100 nucleotides (nts) hairpin-like structure 
termed as the precursor-miRNA (pre-miRNA) in the nucleus. The formed pre-miRNA is trans-
ported out of the nucleus through the interaction with Exportin-5 and Ran-GTP. The exported 
pre-miRNA enters the cytoplasm, where it undergoes further processing ,catalysed by Dicer, to 
form 22-nts double-stranded (ds) RNA product containing both the mature miRNAs guide strand 
(miRNA) and the passenger (miRNA*) strand.  These molecules are loaded by Dicer–TARBP2 
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complex into a large protein moiety, termed as RNA induced silencing complex (RISC) with 
specific regions for the hybridization to 3- UTR region in the target mRNAs.  The silencing 
mechanism may be determined by the extent of base pairing between the miRNA and the target 
mRNAs (partial /complete), resulting in either translational suppression or degradation of the 
mRNA transcripts [11-13]. 
 
 
Figure 2: Biogenesis of miRNA. In nucleus, RNA polymerase transcribes the miRNA gene to produce a 
primary miRNA (pri-miRNA) molecule that undergoes nuclear cleavage (by Drosha and DSCR8) to form 
a precursor miRNA (pre-miRNA). The pre-miRNA is then exported (by Exportin-5 (EXP5)) to cyto-
plasm, where in, it is cleaved (by dicer) to create miRNA:miRNA* duplex. Thereafter, the miRNA du-
plex unwinds and the mature miRNA is assembled into RNA induced silencing complex (RISC). Based 
on the degree of complementary interaction between the mature miRNA and messenger RNA (mRNA), 
translation inhibition or degradation (less common) occurs.  
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1.2.2 MiRNAs Research Approaches 
The wide involvement of miRNAs in gene expression has driven significant research ef-
forts in the miRNA field. The current approaches focus mainly on determining: the presence and 
abundance of miRNAs, the specific targets of miRNAs and, their functional relevance in differ-
ent biological context. 
1.2.2.1 MiRNAs Detection. The identification and detection of regulatory miRNA is essential 
and foremost step in the miRNA research. The particular step is useful to determine whether or 
not miRNA is present and/or regulated in its abundance; and also, since the expression profile of 
the primary transcripts does not importantly corresponds to the mature miRNAs. There are vari-
ous in-practices and -developing techniques to detect miRNA expression profile namely microar-
ray, deep sequencing, real-time reverse transcription polymerase chain reaction, northern blot-
ting, in-situ hybridization etc [14]. 
1.2.2.2 MiRNAs Target determination.  The function of miRNA is ultimately defined by the 
genes it targets, and the consequential effects on their expression. The initial insight in miRNA`s 
targets can be obtained bioinformatically through a number of free available programs; such as 
miRBase and Targetscan. This is followed by more specific validation assays like Genome-wide 
target analysis, 3’UTR-reporter assays (provide functional evidence and even quantitate 3’UTR 
interaction effects in cell-based system) and pull-down assay (identifies the mRNAs that are 
bound to miRNA-processing proteins).  
1.2.2.3 Regulation by miRNAs. The functional relevance of miRNAs is best studied by examin-
ing the phenotypic changes in culture or within an organism. There is now considerable work 
reported, both in vivo and in vitro, to study the regulation by miRNAs [15, 16].  
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1.2.3 MiRNAs as cancer biomarker in diagnosis 
 miRNAs regulate the expression of up to half of the human transcriptome and are well-
studied for their functions in diverse regulatory processes including cell proliferation, cell death, 
fat metabolism, neuronal patterning, hematopoietic differentiation, immunity, etc [17]. Hence, in 
the diseased state, their altered expressions and differential enrichment is reflected in affected 
tissues and body fluids (plasma, serum, urine, etc.), respectively. In addition to differential ex-
pression profile, they are exceptionally stable in biofluids (including blood, urine, saliva, and 
others), as Circulating miRNAs, which allows relatively non-invasive sample collection and the 
collected samples are relatively easy to work within the laboratory settings [18-20]. With these 
useful biomarker characteristics, large research efforts have projected towards finding the sets of 
deregulated miRNA signatures (or miRNA fingerprints) that are representative of a specific dis-
ease. Specifically, a large sum of the total studies are designed to validate miRNAs for their use 
as cancer biomarkers [21]. MiRNAs appear to be located in genomic regions associated with 
cancer or at the sites coinciding with genes frequently rearranged or deleted. In these regions, 
they control important processes such as cell proliferation, apoptosis, and angiogenesis; dysregu-
lation of which plays important role in the onset, progression, and metastasis of cancer [22, 23]. 
Numerous studies have shown distinct altered miRNA profiles in multiple cancer types, such as 
breast cancer, leukemia, liver cancer, ovarian cancer, pancreatic cancer, kidney cancer, prostate 
cancer and many more [24, 25]. Depending on the cellular context and the genes targeted, miR-
NAs can act as oncogene (promotes cancer progression) or tumor suppressor (suppresses cancer 
progression). Therefore, discovering miRNA expression patterns, unique to a particular cancer 
type, is an integral step in identifying biomarker signatures, potentially useful in its diagnosis 
[26].  
 
 
7 
 
1.2.4 Challenges in miRNA detection 
There have been significant efforts invested over the past decade to develop or improve 
miRNAs detection methodologies. However, their detection is still challenging, owing to their 
unique characteristics, namely; short length (18‒26 nts), low physiological abundance (hundred 
to few thousand copies per cell), large differences in melting temperature (due to heterogeneity 
in GC content), homologous sequences among the same family members, presence of the miR-
NA sequence in their biosynthetic precursor units (pre-miRNA), and discrepancies in number of 
expressed copies among different miRNAs. All these create problems in: labeling, selective am-
plification (introduces biases), simultaneous multiplexing studies, specificity and selectivity, and 
the detection of low expression miRNAs [27-39]. 
1.3 Detection of miRNAs  
A wave of significant efforts is being made in combining the sets of such deregulated 
miRNAs into fingerprints (fewer than 10 miRNAs) to allow the discrimination between cancer-
ous and non-cancerous cells [40, 41]. The identification of potential miRNA signatures can be 
performed on a relatively small number of samples by using microarray, a qualitative approach 
capable of simultaneously analyzing thousands of miRNAs. The validation of miRNA signatures, 
yet, requires more accurate quantitative analysis of relatively few miRNAs in thousands of sam-
ples. The analysis of thousands of samples can often be done by the cooperation of many labora-
tories; and essentially requires an analytical technology that is not only accurate, sensitive, tar-
get-specific, capable of detecting multiple miRNAs, but is also direct, fast, robust, and cost ef-
fective in practice [42-44]. Therefore, to better understand the work and development in the field 
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of miRNA analysis, it is important to critically evaluate the currently existing and emerging 
techniques for their clinical applications. 
Classification 
Undoubtedly, there has been a perennial work-flow to create new methodological plat-
forms to satisfy the stringent requirements of miRNA validation assays. Yet, to better understand 
and in turn, evaluate their analytical power and clinical applicability, categorizing them, in prin-
ciple, would be helpful. Notably, more or less all research approaches are integrated with one 
another to provide an efficient detection mode; however, they may be classified, if not strictly, 
based on their detection principle into following categories: spectroscopic, electrochemical and 
miscellaneous methods. 
 
              
1.3.1 Spectroscopic methods  
The analysis of miRNAs by these methods usually involves theoretical and experimental 
analysis of: fluorescent properties, single molecular approaches, electronic absorption and, elec-
tro-optical analysis of molecular interactions, structure and dynamics. The obtained spectra are 
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studied for the relative changes in intensity/shift in presence of miRNAs and, the obtained data is 
integrated and analysed. 
1.3.1.1 Profiling-based methods 
MicroRNA expression profiling is useful for miRNA identification and has been a field of in-
terest for medicinal and biological research groups.  Northern blotting analysis was previously 
the most standardized method for miRNA detection and still remains a gold standard for miRNA 
expression profiling, determination of their size and validation of predicted miRNAs (Figure 3) 
[44, 45]. However, there are some technical limitations that prevent its routine use including: low 
sensitivity, inability for multiple miRNAs detection, multiple handling steps and time-consuming 
procedures. Several labs had developed novel Northern blot version to improved sensitivity and 
reduce assay time, by either incorporation of Locked Nucleic Acid (LNA) or replacing conven-
tional UV-cross-linking of RNA to chemically cross-linked nylon membrane [46, 47]. Recently, 
Bang and colleagues combined Northern blotting with laser ablation inductively couple mass 
spectrometry and employed lanthanide-labeled DNA probes for quantitative detection of multi-
ple miRNAs [48]. Though the method offered improved sensitivity and specificity in simplex 
samples but the individual signals in the multiplex samples were indistinguishable, and moreover 
the assay was time-consuming; therefore is not practical in clinical studies, which require the de-
tection of multiple and large numbers of RNA sample [14].  
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Figure 3: Schematic of Northern blotting 
 
Currently, microarray represents the most widely used high-throughput method (Figure 
4) for detecting the miRNA levels and particularly, to simultaneously screen large numbers of 
miRNAs signatures of various developmental stages and disease progression [49, 50]. However, 
the technique is challenged by several innate miRNA characteristics like short length (hampering 
both sensitivity and selectivity of the system), low abundance of certain miRNAs to total RNA 
content (<0.01%), and sequence homology among the family members. To overcome these chal-
lenges, in recent years, several nucleic acid analogues, like LNAs, are employed for their superi-
or sensitivity [27, 51]. Reputed for miRNA identification, microarray lacks the ability to provide 
quantitative data, as the provided relative signal intensities do not rank the level of miRNAs 
abundance. Ultimately, large sample requirement and high expense in the fabrication of microar-
ray chip limits its routine application in basic and clinical research laboratories [14]. 
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Figure 4: Schematic of Microarray 
 
The other method known for its ability to monitor specific miRNA expression profiles and to 
provide spatiotemporally semi-quantitative data at the cellular and subcellular levels is in-situ 
hybridization (ISH). The technique is, however, impeded by low expression levels and reduced 
probe-binding affinity of miRNAs, due to their small size. Some innovations are put forward, 
either with the use of LNA probes, RAKE, hapten-like oligoes, tyramide signal amplification 
[52-57], to make ISH a robust and sensitive miRNA detection assay, but due to low quantifica-
tion power and throughput, its use in diagnostics is limited [14]. 
1.3.1.2 Fluorescent correlation microscopy 
 The method uses microfluidic, multicolor laser system (capable of counting individual mol-
ecules) to distinguish among different molecules in solution, based on their unique spectral prop-
erties as they flow at high velocity through the system. Neely lab employed dual probe labeling 
system in conjugation with fluorescent correlation spectroscopy to count and quantify single 
molecules of miRNAs [58]. Li et al used Luminex xMAP array, a microsphere-based multiplex 
system capable of simultaneously detecting up to 100 analytes using one fluorescent reporter. 
Though straightforward, the method requires miRNA extraction and also, if the probes are not 
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sterically-bound (to quench the fluorescence of labeled probes in the absence of miRNAs) to the 
microspheres, they might result in increased background noise [59]. There are several other new-
ly emerging methods for detection and quantification of miRNAs, such as; Lee and co-workers 
used graphically encoded hydrogel microparticles with fluorescent microscopy [60], the meth-
od is advantageous for its direct approach and sensitive detection, but require special and sophis-
ticated instrumentation.  
1.3.1.3 Nanotechnology-based methods  
Several spectroscopic methods using nanotechnology have also developed in clinical science 
due to their exceptional photoelectric property, size and surface effects. For instance, label-free 
Surface-enhanced Raman spectroscopy for miRNA analysis. Though the method is rapid, it 
has certain shortcomings, such as, the spectra must be obtained individually prior to the assay (so 
as to identify the representative Raman shift) and also, sequences with overlapping peak cannot 
be differentiated, especially in presence of complex (biological) matrices. Zhou et al recently de-
signed SERS sensor-based sandwich hybridization assay (as shown in Figure 5) for multiplexed 
miRNAs detection and quantification [61]. Despite the innovation being made, SERS technique 
requires sophisticated read-out system, specific analytical skills and convoluted data interpreta-
tions and verifications, rendering it rather impractical for molecular biology laboratories.  
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Figure 5: SERS-based sandwich hybridization assay: A) Schematic of the SERS-based sandwich hybrid-
ization assay which involves the reaction of SERS nanoprobes (with DNA probes complementary to 
miRNAs) and the Ag microspheres (with capture DNA, the miRNA first gets captured by Ag-HMS (sil-
ver hollow microspheres), followed by hybridization with SERS nanoprobes forming multiple sandwich 
hybridization complex. B) (a) Raman spectra obtained for simultaneous three miRNAs detection; 
(b)(c),(d) Standard curve between SERS intensities with log concentration of mir-21, miR-122 and miR-
223, respectively. Adopted by Zhou et al [61]. 
 
Nanotechnology is also exploited for live cell miRNA imaging with regards to efficient load-
ing and cellular delivery. Ryoo et al presented graphene oxide based miRNA sensor for quantita-
tive monitoring of multiple miRNAs in living cells using dye-labeled PNA probes with low de-
tection limit and high specificity [62]. Other work utilized amplification-based detection by the 
combination of gold-nanowires with quantum dots for miRNA live-cell imaging [63-65]. How-
ever, the need of special and costly equipment and background interferences of complex matri-
ces, during analysis, makes them less robust. 
1.3.1.4 Amplification-based methods 
In the class of spectroscopic methods, to overcome the challenge of low physiological abun-
dance of miRNAs, many lab groups have developed amplification-based assays to improve the 
sensitivity of the method by multifold. The quantitative RT-PCR (reverse transcription polymer-
A 
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ase chain reaction) is a well-known gold standard for miRNAs gene expression quantification 
(Figure 6). Several innovations, like extending the size of the mature miRNA by primer exten-
sion or using poly-A polymerase have also been reported [66, 67]. Unfortunately, these assays 
are costly for routine use in diagnostics, do not provide absolute quantification data and are 
prone to amplification-based biases. 
 
 
Figure 6: Schematic of RTqPCR using fluorescent quencher. The miRNA is firstly reverse transcribed to 
complementary DNA (cDNA), the formed cDNA undergoes the PCR cycle of denaturation, annealing 
(using forward and reverse primers) and elongation. During the elongation, the forward primer does the 
strand displacement reaction to release the reporter from quencher bonded probe to generate fluorescence. 
 
The use of non-DNA polymerase enzymes (like endonuclease DNAase I) for amplified 
miRNA multiplexing studies using GO-protected polydopamine nanosphere DNA (multicolor 
sensor) fluorescent probes is also reported [68]. Despite an attractive approach, there are possi-
bilities of high background noise and/or false signal due to failure in quenching. Several research 
groups have also performed Ligase chain reaction (LCR) [69, 70], Rolling Circle Amplifica-
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tion (RCA) [71, 72] and one-step exponential amplification reaction (EXPAR) [73] for highly 
sensitive miRNAs detection.	 Another kind of enzyme-based amplification work is done using 
surface poly A-enzyme chemistry and gold nanoparticle-amplified SPRI measurements to detect 
multiple miRNAs at attomolar levels [74]. These methods have high quantitative power but the 
main technical limitations are:  requirement of sophisticated and expensive instruments for signal 
readouts and, signal dependence on temperature.  
To sum up, all the amplification–based methods have a long run-time to quantify miRNAs 
and may therefore delay prompt diagnosis. Additionally, they have disadvantages of high cost, 
lack of custom-made oligonucleotide probes, high levels of background fluorescence (due to in-
complete fluorescence quenching), relatively poor reproducibility with increasing cycle number, 
and the most important, the need for amplification (risks of contamination and error during each 
amplification step); all these overweigh their potential clinical use [75, 76]. 
1.3.1.5 Bioluminescense spectroscopy 
  Bioluminescense detection methods have also developed for solid and in-solution miR-
NA analysis by Cissell and offer advantages of minimal sample preparation, high throughput 
parallel analysis and high signal-to-noise ratio (Figure 7) [77, 78]. However, the method relies 
on decrease rather than increase in signal, which might pose a problem for detecting low abun-
dance miRNAs.  
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Figure7: Schematic of bioluminescence-based hybridization assay for miRNA detection which utilises 
protein complementation (reporter protein) of the luminescent enzyme Rluc. 
 
1.3.2 Electrochemical detection methods 
Electrochemical detection technology is among the emerging arena in terms of offering 
simple, efficient, and low-cost methods for quantitative miRNAs analysis. Monitoring the re-
sistance of Peptide nucleic acid (PNA) functionalized silicon nanowires reported miRNA detec-
tion limit of 1 fM [79]. Another group used PNA capture probes immobilized onto a nanogapped 
biosensor array for miRNA analysis to provide a good dynamic range [80]. Gao and colleagues 
utilized direct chemical ligation to tag miRNAs, in a total RNA pool, with an electrocatalytic 
moiety [81, 82]. For quantitative multiplex detection, Berezoski et al designed 3-mode displace-
ment-based electrochemical biosensing device [83]. The technique is highly sensitive and selec-
tive, yet being challenged by convoluted sample preparation which often introduces errors. Fur-
thermore, the electrochemical detection instruments are usually not available in most laboratories 
which impede its widespread application in diagnosis.  
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1.3.3. Sequencing-based Methods 
Next generation RNA sequencing has proved to be appreciably useful profiling technique 
to reveal the differential expression of miRNAs in several diseases and being capable in discrim-
inating between homologous miRNA sequences [84, 85]. Extremely useful in the identification 
of miRNAs, their quantification abilities are still questionable.  
1.3.3 Miscellaneous methods  
These are other emerging methods in the field of miRNAs analysis. Lately, biosensing 
devices received considerable attention, example of which includes microfluidic devices and pa-
per-based systems [86-90]. They are advantageous in terms of simplicity, sensitivity (in attomo-
lar range), point of care and prompt miRNA analysis. However, they require miRNA extraction 
(variability in RNA yield), technical expertise and also their multiplexing abilities are doubtful.  
Currently, NanoString technology has gained remarkable research panel interest of being a 
powerful identification and validation tool for miRNA biomarkers, by identifying their differen-
tial expressions in normal and cancerous state  with appreciable sensitivity [91]. Though being 
direct and amplification-free; the method might not be sensitive for the detection of downregu-
lated miRNAs; additionally, it is time-demanding (2 days) and requires very expensive consum-
ables. 
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1.4 MiRNA analysis using Capillary Electrophoresis 
 
 
 
 
Figure 8: Schematic of Capillary Electrophoresis-based Hybridization assay 
 
Capillary electrophoresis (CE)-based detection system (Figure 8) is another fast 
growing method for miRNA analysis. It is a useful analytical tool which offers advantages such 
as: high-throughput capability, good separation efficiency, rapid and cost-effective RNA and 
DNA analysis [92, 93].	In addition, the combination of CE with laser-induced fluorescence (CE-
LIF) is one of the most sensitive detection modes in CE, providing great sensitivity and specifici-
ty for the analysis of trace biomolecules in complex sample matrices such as cell lysates, tissues, 
and various other biofluids [94, 95]. 
The use of CE for miRNA detection has been attempted since 2008, Li et al  reported on 
miRNA and its methylated form (a crucial product in plant miRNA biogenesis), using capillary 
gel electrophoresis (CGE) and capillary zone electrophoresis (CZE) modes of separation [96]. 
Following, Chang et al CE-analyzed miRNA in nasopharyngeal carcinoma cell lysate without 
any non-specific interferences [97]. Since then, many researchers have presented various work 
related to miRNA detection using microchip or common CE systems [43, 98]. However, CE 
methods must overcome the problems, associated with separation efficiencies, sensitivity, speci-
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ficity, and multiple target analysis, for them to be utilized in the screening and biological study 
of miRNAs in clinical samples. To address these, several appreciable works have been attempted 
to develop methods for the simultaneous, specific and sensitive detection of multiple disease-
specific miRNA biomarkers in biological fluids. Above all, methods to improve the detection 
sensitivity of miRNAs in physiology are developing at faster pace.[99] Most of them are hybrid-
ization-based, principally involving the interaction between the miRNAs and their complemen-
tary labeled probes to form the respective hybrids/duplexes. Importantly, the hybridization effi-
ciency is directly depended on the results obtained at specific hybridization conditions such as 
temperature, buffer components, and time. Therefore, determining the best hybridization condi-
tions is necessary for the proper detection and analysis of trace amounts of miRNAs in complex 
biological samples [100].  
Along with optimization of the hybridization conditions, the use of isotachophoresis 
(ITP) has been also reported to concentrate miRNAs in capillary columns by using CE or micro-
chip CE systems.	ITP is an electrokinetic focusing technique that utilizes a buffer system, com-
posed of leading and tailing electrolytes with different conductivity or pH, to achieve sample 
preconcentration for more sensitive detection. Among these attempts, Schoch et al reported ITP 
technology for fast and ultrasensitive detection of small RNAs from total human RNA allowing 
the extraction, preconcentration, and quantification processes on the microchip CE system [98]. 
Garcia- Schwarz and Santiago achieved near 1 pM detection limit of miRNA in less than 10 min 
using ITP [101]. Further developments in CE detection systems and/or enrichment processes 
have also been continuously investigated to improve the assay sensitivity. The detection of mul-
tiple miRNAs in CE system is, usually, achieved using multiple detectors or probes. In addition, 
CE has been also combined with other assay methods to investigate the biological functions of 
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miRNAs, such as characterization of the miRNA binding site in miRNAs genes as well as quali-
ty control of extracted miRNA from biological samples [100, 102, 103]. Berezovski and cowork-
ers developed a quantitative method for miRNA analysis in blood serum with protein-facilitated 
affinity CE with high sensitivity (300 molecules per microliter); they used single-stranded bind-
ing (SSB) protein (binds to fluorescently labeled DNA probe) and double stranded RNA binding 
protein (p19) (binds to DNA-miRNA Duplex) to facilitate separation. However, their method 
involved pre-concentration using PCR and also, scaling for multiple miRNAs analysis was ques-
tionable [104]. The same group further designed label-free and PCR-free protocol for direct de-
tection of cancer- related endogenous miRNAs combining CE with electrospray ionization-mass 
spectrometry. Though method is direct, however, its quantification power is low [105]. Sets of 
miRNAs are also been used for performing body fluid identification using CE and proven to 
have similar discriminatory power as qPCR [106]. 
Though appreciable work using CE-based hybridization assay has been reported in the 
field of detection and quantitative analysis of miRNAs, but the use of excess of complementary 
probes (which render similar electrophoretic mobilities as to formed miRNA-probe hybrids) pos-
es separation difficulties and therefore, affects the accuracy of miRNA quantification. In addi-
tion, in the light of multiplexing studies, miRNAs being nearly similar in terms of charge and 
size, their separation from each other in CE is another bottle-neck needed to address for the clin-
ical application of CE-based miRNA hybridization assays. Nonetheless, with sound knowledge 
of the limiting factors and their underlying mechanisms, researchers have come up with ap-
proaches to overcome them. Our lab, also put in intense efforts in this arena and presented an 
amplification-free direct quantitative analysis of multiple miRNA (DQAMmiR) using CE-based 
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hybridization more than a decade ago and since then, have continuously worked to improve it 
even further. 
 
1.5 Direct Quantitative analysis of multiple miRNAs (DQAMmiR) 
 
Figure 9:  Schematic of direct quantitative analysis of multiple miRNAs. The CE-based hybridization-
assay involving the hybridization of miRNAs with their complementary probes (with/without drag tags) 
and taking the advantage of separation abilities of CE to resolve the hybrids and excess unbound probes 
for the accurate quantification of miRNAs using mathematically derived equations. 
 
The direct quantitative analysis of multiple miRNAs (DQAMmiR) Figure 9, worked and 
developed by our lab, is the first direct assay that did not require any target modifications and 
provided absolute miRNAs quantitative data. Briefly, it is a hybridization assay which utilises 
the separation abilities of capillary electrophoresis to analyse multiple miRNAs. To address the  
(earlier mentioned) separation inefficiencies, two following approaches were used: 1) the addi-
tion of single-stranded binding protein (SSB) in the CE running buffer to separate hybrids from 
excess unbound probe and, 2) the conjugation of peptide drag tags on the complementary oligo-
nucleotide probes to separate the hybrids from each other during multiple miRNAs analysis. 
Since the method inception, efforts were made to improve the multiplexing abilities, limit of de-
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tection and specificity. For simultaneous detection of five miRNAs, different length peptide tags 
(acted as mobility shifters) were conjugated to the respective DNA/LNA probes in order to re-
solve the similar mobility hybrids from each other. Furthermore, to reduce the overall assay time 
by the use of large probe concentration relative to target, a purification procedure was used to 
significantly reduce the probe impurities and accelerate the hybridization kinetics. Combining 
DQAMmiR with capillary isotachophoresis, (in-capillary pre-concentration technique) was an-
other benevolent innovation that improved the limit of detection by two orders of magnitude, 
scaling our assay to low abundance miRNAs.  The assay by this stage was highly sensitive and 
accurate in analysis, however, sequence homology of different miRNAs posed the specificity 
problem, which our group solved by: 1) introducing LNA bases to DNA oligonucleotide probes, 
which improved the specificity by increasing the Tm (melting temperature) of the hybrids and, 2) 
running CE under dual-temperature mode, i.e., high capillary temperature at the beginning for 
specific hybridization, followed by low capillary temperature for the following CE run, to avoid 
any adverse effects on electrophoretic separation of the hybrids. With this, the assay was specific 
to even a single nucleotide mismatch and added to the overall benefits of the DQAMmiR.  
Yet, despite of being a well-developed approach, the assay lacks the robustness for work-
ing at different CE temperatures; in terms of introduction of a protein (SSB) for the separation of 
target-bound probes from target-unbound probes. SSB being a protein is quite thermolabile and 
also might have some quenching phenomena on the fluorescently labeled probes which could 
overall decrease the assay potential along with increasing the cost, making it less likely suitable 
for clinical setups [40, 42, 107-113].
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Chapter Two 
PEPTIDE NUCLEIC ACID (PNA)-FACILITATED DQAMIR 
 
The presented material was published previously and reprinted with permission from Hu, L.; 
Anand, M.; Krylova, S.M.; Yang, B.B.; Liu, S.K.; Yousef, G.M.; Krylov, S.N. Direct quantitative 
analysis of multiple microRNAs (DQAMmiR) with peptide nucleic acid hybridization 
probes. Analytical Chemistry 2018, 90, 14610–14615. 
 
Here we introduce the second-generation DQAMmiR, which is simpler than the first-
generation assay, as it does not need Single Stranded Binding protein (SSB) and requires only 
peptide drag tags on the probes to carry out the simultaneous quantitative analysis of multiple 
miRNAs. The reason for using SSB in the first-generation DQAMmiR was to separate the excess 
unbound ssDNA probes from the ssDNA-miRNA hybrids. The probes and hybrids, otherwise, 
cannot be resolved due to their similar electrophoretic mobilities with regards to similar charge 
to size ratio (negative charges on both DNA and miRNA strands). SSB would not be needed if 
the probes are polymers capable of hybridizing miRNA but are not negatively-charged. An ex-
ample of such polymers is peptide nucleic acid (PNA), an electrically neutral analogue of DNA 
[114]. 
 
 
 
 
 24 
 
2.1 Introduction to PNA 
 
Figure 10: Structural comparison between different probes employed in hybridization assays; DNA, PNA 
(Peptide Nucleic Acid) and LNA (Locked Nucleic Acid) probes. There is difference in the backbone 
among the three probes: Blue: negatively charged ribose phosphate units in DNA, Orange: uncharged N-
aminoethyl glycine units in PNA, and Green: O-linker between C1 and C4 in negatively charged ribose 
phosphate units in LNA. 
 
PNAs (Figure 10), are engineered uncharged oligonucleotide analogues, first synthesized 
by Nielson et al (1991) [115], in which, the neutral polyamide scaffolds (N-(-2-aminoethyl gly-
cine units) replaces the usual negatively charged phosphodiester backbone, yet homomorphous 
to DNA, with respect to the number of backbone bonds and the distance between the backbone 
and the nucleobases. PNA oligomers are solid phase-synthesized using Bhoc (benzhy-
dryloxycarbonyl) or Fmoc (9-fluorenylmethoxycarbonyl chloride) chemistry. Nielson and group 
used Bhoc chemistry with an automated peptide synthesizer.[116] However, the particular in-
volves the repetitive use of extremely hazardous trifluoroacetic acid. On the other hand, Fmoc 
uses much milder reaction conditions and can also be used with DNA synthesizer (unlike Boc); 
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nonetheless, it produces PNA oligomer with more impurities, some generated by trans-acylation 
reaction which are difficult to separate because of identical molecular weight and similar proper-
ties [117]. Recently Bts chemistry, developed by Panagene, uses self-activated building blocks 
which produce more pure form of PNAs. Importantly,  it does not add building blocks to a mis-
behaved product and hence, the impurities are of smaller molecular weight and can be easily re-
moved by HPLC purification [118].   
PNAs offer stronger hybridization behavior to complementary DNA, RNA or PNA itself 
and the formed duplexes have high thermal stability and unique ionic strength effects [119]. The 
distinct physio-chemical properties of PNAs, such as great biological stability (resistant to nucle-
ases, proteases, etc.), appreciable chemical simplicity, excellent nucleic acids binding properties 
(lack of repulsion in reaction due to its uncharged backbone) even at low ionic strength condi-
tions (which discourages the annealing of complementary genomic strands) [120], and much of 
our interest, the uncharged electric behavior, compared to partial negative nature of potential 
PNA‒miRNA hybrids, make them the probe of choice for DQAMmiR. 
There are quite a few previous reports of using PNA in CE-based hybridization assay for 
the analysis of small ss-oligos, the earliest work on PNA was presented by Perry et al in CE-LIF 
showing decent separation between the formed PNA‒ssDNA hybrid and the excess unbound-
PNA, reflecting the mobility difference between the two under the applied electric filed; addi-
tionally, the lab also reported PNA`s ability to detect single and double nucleotides polymor-
phism in presence of  a denaturant [120].  Following this, the other group also validated the spec-
ificity of PNA probes to single nucleotide polymorphism (SNP) in CE-LIF probe assay for sin-
gle-base pair mutated DNA [121]. The experimental results showed PNAs as less tolerant to 
mismatches (the formed mismatch hybrid are unstable due to reduced Tm (loss of 8‒25 °C)). In 
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addition, there are some reported qualitative and quantitative binding studies of PNA to target 
ssDNA/ RNA in multiple CE modes, showing the stability and comparatively more favorable 
binding properties [122]. Alternatively, Ostromohov group presented ITP-based amplification-
free assay using PNA for rapid and highly sensitive (LOD~100fM) detection of short-chain nu-
cleic acids with improved S/N ratio [123]. The peptide backbone in PNA is readily available for 
chemical modifications like attaching peptide chain, PEG polymers, etc; to enhance its nucleic 
acid binding or convey other desired properties to the molecule [92, 93, 124]. 
The use of PNA in the field of miRNA analysis has since been confirmed by a group who uti-
lised PNA in the form of ‘fluorogenic biosensors’ to target miRNAs specific to prostate cancer 
[125]. A quantitative and multiplexed miRNA sensing system (PANGO) in living cells was de-
signed by Ryoo et al which showed detection limit as low as ~ 1 pM [62]. The other useful ap-
plications of this uncharged synthetic oligonucleotide include; PNA-microarray for miRNA ex-
pression profiling and also, in-vitro studies indicate their use in antigene, antimiR and antisense 
therapies [126].  
 
2.2 Justification for the use of PNA in DQAMmiR 
As noted, the physiochemical properties of PNA and previously performed work quite 
clearly justify its potential use to solve the inherent separation inefficiencies encountered in CE-
based probe assay. PNA-facilitated DQAMmiR involves the hybridization of fluorescently-
labeled PNA probes to the complementary negatively charged miRNAs to form stable duplexes 
(PNA‒miRNAs) in solution, followed by detection, separation and quantification of excess 
probes and hybrids in CE-LIF mode (which separates molecules based on the difference in 
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charge : size ratio). An improved separation between the hybrids and excess PNA probes is ex-
pected, likely omitting the need of an external mobility shifter (such as SSB). However, PNA 
have certain limitations in use; unlike, usual charged oligonucleotide probes, the hydrophobicity 
of PNA promotes self-aggregation and nonspecific adherence, posing technical challenge for its 
handling in solution, and particularly in our assay, the probability of sticking to the capillary 
walls (severely affecting miRNA quantitative accuracy) [127]. To combat the solubility issues, 
some structural modifications to PNA have been reported: addition of amino acid residues at 
their termini [128], conjugation to charged DNA molecules,[129] or to high molecular weight 
polymers like PEG [130]. We, in our assay, employed PNA probes attached to adjacent O-
linkers/AEEA (2-aminoethoxy-2-ethoxy acetic acid) which acts as solubility enhancer and also 
added 20% acetonitrile (ACN) to the CE running buffer. Not only ACN aids the delivery of PNA 
into the solution but also prevents PNA sticking, by forming a hydrophobic layer on the capillary 
walls. In addition, since the viscosity of ACN is less than water-based solution, therefore, the 
effect of 20% ACN tends not to adversely affect Electroosmotic flow (EOF) in CE, which was 
further justified by theoretical calculations of viscosity and obtained experimental results [131]. 
However PNAs, being uncharged pseudo-oligonucleotides have physiochemical proper-
ties significantly different from commonly employed polyanionic oligonucleotides, therefore, 
any experimental conditions optimized for hybridization or CE analysis for usual oligonucleo-
tides cannot be concluded as optimal for PNA. Nonetheless, to achieve the absolute quantifica-
tion of multiple miRNAs simultaneously, a decent separation of individual PNA‒miRNA hy-
brids from each other is the most needed. Hence, peptide drag tags will be attached to PNA 
probes (similar to first generation DQAMmiR) to alter the mobility of the hybrids. All things be-
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ing considered, we planned our experimental layout as follows; 1) Analysis of a single miRNA, 
2) Analysis of multiple miRNAs. 
 
2.3 Analysis of a single miRNA 
The initial method development for efficient hybridization and CE separation was 
achieved by performing a single miRNA analysis. The prime goal for this study was to achieve 
the separation of target-bound and target-unbound excess probe. For this, a single miRNA was 
selected (hsa-miR-21) and the conditions for hybridization (target and probe concentrations, 
temperature, buffer components, incubation time, etc.) and CE-LIF detection were determined. 
For quantitative purpose, we incubated different miRNA concentrations (500 pM–31.25 pM) 
with constant 10 nM PNA probe in triplicates and the obtained CE-data was precisely quantified. 
2.3.1 Method and Materials 
2.3.1.1 MiRNA and complementary PNA probe. The miRNA (5’-UAG-CUU-AUC-AGA-
CUG-AUG-UUG-A-3’) was custom-synthesized by IDT (Coralville, IA, USA) and the fluores-
cently-labeled PNA probe (Alexa 448-O-5’-TCA-ACA-TCA-GTC-TGA-TAA-GCT-A-3’) was 
custom-synthesised by PNA Bio, Inc. (Newbury Park, CA).The other chemicals were obtained 
from Sigma-Aldrich (Oakville, ON, Canada) unless stated otherwise.  
2.3.1.2 Hybridization Conditions. The hybridization reaction was performed in Mastercycler 
5332 thermocycler (Eppendorf, Hamburg, Germany). Various concentrations of miRNA were 
incubated with 10 nM PNA probe in CE-running buffer. The temperature was increased to a de-
naturing 95 °C and then lowered to 60 °C at the rate of 20 °C/minute and was held to 60°C for 
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30 min to allow annealing. In order to minimize miRNA degradation, a nuclease-free environ-
ment was maintained. 
2.3.1.3 CE-LIF. All experiments were performed using a P/ACE MDQ CE instrument (Beck-
man-Coulter, Fullerton, CA, USA) equipped with a LIF detector. A 488 nM line of continuous 
wave solid-state laser (JDSU, Santa Rosa, CA, USA), with 1 mW effective output was utilized to 
excite fluorescently labeled probes. Fluorescence signal was detected at 520 nM wavelength. A 
bare fused-silica capillary with an outer diameter of 365 µm, an inner diameter of 50 µm, and a 
total length of 80 cm was used. The distance from the injection end of the capillary to the detec-
tor was 70 cm. Prior to each run, the capillary was flushed with 0.1M HCl, 0.1 M NaOH, deion-
ized H2O, and the running buffer (20 mM borax 20% (v/v) acetonitrile pH 9.0) for 2 minutes 
each. Samples were injected at the positive end by a pressure pulse of 0.5 psi for 5seconds; the 
volume of the injected sample was ~ 6 nL. Electrophoresis was driven by electric field of 312.5 
V/cm applied voltage and at coolant controlled temperature 20 °C. The electropherograms were 
analysed using 32 Karat software. Peak areas were divided by the corresponding migration time 
to compensate for the dependence of the residence time in the detector in the electrophoretic ve-
locity of analyte. 
2.3.1.4 Spectrophotometric Determination of Target and Probe Concentrations. The target 
and probe concentrations were determined by light absorption at 260 nm using the Nano-Drop 
ND-1000 spectrophotometer (Thermo-Fisher Scientific). The stock concentration of the target 
and probe was too high to measure directly; therefore, a small sample of the each stock solution 
was serially diluted, and absorbance of each sample at 260 nm was measured 5 times. The con-
centration of each sample was determined as absorbance/εl where ε is the molar extinction coef-
ficient of the miRNA-21 and PNA probe at 260 nm respectively (provided by IDT/PNA Bio) and 
 30 
 
l is the optical path length. Using the concentrations of the serial dilutions, the original stock 
concentration was extrapolated. 
2.3.2 Result and Discussion 
2.3.2.1 Separation between the excess probe and PNA‒miRNA hybrid in CE. The separation 
between excess probe and formed hybrid is the foremost requirement to accurately quantify the 
miRNA concentration and indeed to justify the use of PNA in DQAMmiR. For the given exper-
iment, 1 nM miRNA-21 was allowed to hybridize with 10 times higher PNA probe concentration 
(10 nM), followed by CE-LIF detection. The obtained electropherogram showed an excellent 
separation between excess probe and formed hybrid (Figure 11A).  
 
     
Figure 11:  A) CE separation of a PNA probe from a PNA‒miR-21 hybrid in a run buffer of 20 mM bo-
rax 20% (v/v) acetonitrile pH 9.0. The sample was prepared by incubating 1 nM of miR-21 with 10 nM 
PNA probe. Separation was driven by an electric field of 312.5 V/cm at 20 °C. B) Quantitative plot 
between PNA-facilitated DQAMmiR measured concentrations and spectroscopically determined 
concentrations (31.25 pM‒500 pM)  at 260 nm  for  miR-21. The dashed line (y = x) represents a line 
corresponding to 100% recovery. Error bars represent standard deviations from mean values obtained 
from three experiments. 
 
(A) (B) 
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2.3.2.2 Quantitative analysis of miRNA 
2.3.2.2.1 Determination of Quantum Yield (qH). Assuming that the probe can be baseline sepa-
rated from the hybrid, the quantum yields of the target-bound probe, q can be found from two 
sets of data obtained for the same amount of the probe with and without the target, respectively: 
 
 
Here, 𝐴Ƥ#is the fluorescent signal of the probe for no target and 𝐴Ƥ and 𝐴$	are fluores-
cent signals of the remaining target-unbound probe and target-bound probe, respectively, for a 
nonzero target concentration. 
2.3.2.2.2 Determination of miRNA concentration. Theoretical Consideration; we assume that 
the labeled PNA probe hybridizes with the miRNA in a process that goes to completion: 
PNA + miRNA à PNA‒miRNA                                        (1)                                      
  The probe is taken in excess to the miRNA. In equilibrium, the initial amounts of the 
probe and target, P0 and miRNA, are linked with the amounts of the remaining probe, P and 
formed hybrid, PNA‒miRNA, as: 
[P0] = [PNA‒miRNA] + [P]                                         (2)                                      
For [P0] ›› [miRNA] & [P0] ›› Kd, hence; 
[PNA‒miRNA] = [P0] ‒ [P]                                        (3) 
In the equation (3), the amounts could be expressed in any conventional units such as 
moles or number of molecules. In the following work, symbols A with corresponding indexes 
H
H
P
Aq
A A
=
-
0P
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denoted measurable areas of peaks in electropherograms, equivalent to integrated fluorescent 
signals and was presented in arbitrary units. To compensate for differences in the residence time 
in the detector, the areas were divided by corresponding migration times. The quenching effects 
of the target annealing were also taken into account by the introduction of qH as the relative 
quantum yield of the target-bound probe with respect to that of the unbound probe. 
                                                                     (4)                                      
                                               (5)                                      
Using equation (4) and (5) in equation (3);  
 
We could express the initial total amount of the probe as; 
                                                              (6)                                      
Hence, 
                                                                   (7)                                      
The final amount the miRNA could be found by substituting the coefficient a from equa-
tion (7). On simplification the final equation was obtained as follows; 
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                                                         (8)                                      
Hence, the target concentration was a function of initial concentration of the probe, area 
of the target-unbound and target-bound probe, and the quantum yield; 
[miRNA] à f ([P0], AP, AH, qH) 
In above expression, [P0] is known; qH could be determined prior to the sample analysis; 𝐴$	, 𝐴', 𝐴Ƥ#could be measured by CE run directly. 
2.3.2.2.3 5-point Quantification for a Single miRNA. The quantitative analysis was performed 
for different concentration of miRNA (500, 250, 125, 63.5, and 31.25 pM) incubated with a con-
stant PNA probe concentration (10 nM), followed by CE analysis. The CE results were quanti-
fied (Table 1) and the measured concentrations were plotted against the spectroscopically deter-
mined concentrations (Figure 11B). A recovery between 90–113% and RSD <15% indicated the 
accuracy of the assay. 
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Table 1: Quantification results and recovery (%) obtained from PNA-facilitated DQAMmiR for a single 
miRNA analysis corresponding to the actual concentrations as determined by spectroscopically at 260 
nm. Standard deviations from mean values were obtained from three experiments. 
Actual concentra-
tion (pM) 
PNA-faciliated DQAMmiR concentration 
(pM, Mean ± Standard Deviation) 
    Recovery (%) 
500 502 ± 11 100 
250 249 ± 5 99.6 
125 135 ± 6 108 
62.5 71 ± 8 113 
31.25 33 ± 2 105 
 
 
2.3.3 Conclusion 
The basic goal to carry a single miRNA analysis was to check the feasibility of PNA 
probe in DQAMmiR, but more particularly to achieve decent separation between the excess of 
PNA probe (uncharged) and formed PNA‒miRNA (partially negatively charged) in CE. The pre-
liminary data well-established the use of PNA in omitting SSB (as mobility modifier for un-
bound probes) in DQAMmiR.  
 
 
2.4 Multiple miRNA Analysis 
Often, different miRNAs collectively regulate important cell regulatory events and, thus 
can be simultaneously involved in the progression and development of diseases. Therefore, it 
becomes useful and often necessary to monitor multiple miRNAs at the same time to better un-
derstand the diseased state. The detection of multiple miRNAs is also useful for the discovery of 
new biomarkers and/or to monitor multiple biomarkers for the improvement of specificity and 
sensitivity of diagnostic tests.  
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2.4.1 Theoretical estimation of PNA–miRNA hybrids mobility 
PNAs possess negligible charge; yet the size of PNAs differ only slightly from usual oli-
go (ssDNA, RNA) in terms of rise in the length per base pair addition; possibility due to the dif-
ference in the backbone units (N-aminoethyl glycine instead of ribose phosphate units). Keeping 
this in mind, (as earlier being designed for DNA‒miRNA hybrids), a theoretical model for PNA‒
miRNA hybrids was evolved, by Liang Hu, Ph.D candidate in our lab, to predict their electro-
phoretic mobilities in CE, with strict consideration of probable variations for PNA probes in rela-
tion to usual DNA probes. Similar to DNA‒miRNA, PNA‒miRNA hybrid was assumed to be a 
rigid rod, as for short nucleobase hybrids [132]; 
Lhyb << bK 
Here, Lhyb is the contour length and is equal to Nhyb.b, in the range of 4‒6 nm for possible 
PNA‒miRNA hybrids (Nhyb is the number of base pairs, 18‒25 nts for miRNAs; and b is the hel-
ical rise per nucleobase, 0.24 nm for PNA‒RNA hybrid [133],  and bK is the Kuhn length which 
is though not yet reported for PNA‒RNA hybrids, but the latter has proven to be stiffer as com-
pared to dsDNA (for which bK is in the range of 30‒50 nm) [134].  Hence, PNA‒miRNA hybrid 
was assumed to be a stiff rod moving along the capillary axis under applied voltage. Taking the 
model as the lead, the CE-mobilities for possible PNA‒miRNA hybrids were estimated. Follow-
ing the expression of two forces, i.e. electric force (FE,hyb) and hydrodynamic frictional (Ff,hyb) 
force, acting on species [135, 136]:  
                                                                                                                    (9)                                      
                                                                                                       (10) 
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Here, E is the applied electric field, zi is from the literature, dhyb is the diameter for PNA‒
RNA hybrid, calculated as 3.5 nm [133]. The viscosity, η for 20 % acetonitrile buffer solution 
was comprehended from the earlier reports as 1.1 mPa.s [137] and the Bjerrum length was calcu-
lated as 0.79 nm using; 
                                                 (11)                    
In equation (11), elementary charge, e is 1.602 × 10–19 C; vacuum permittivity, ε0 is 8.85 
× 10–12; relative dielectric constant, εr is  ̃72 [136], Boltzmann constant, kB is 1.38 × 10–23 at abso-
lute temperature, urel is the velocity of the hybrid in the running buffer. Hence, the mobility of 
the PNA‒miRNA hybrid could be estimated by balancing the electric and hydrodynamic forces 
FE,hyb = Ff,hyb                                                     (12) 
From equation (9), (10), and (12),  
                                   (13) 
Since, , where µhyb is the electrophoretic mobility of the hybrid; therefore, 
equation (13) could be expressed as; 
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According to the equation (14), it could be derived that the electrophoretic mobility of the 
hybrid was dependent on the number of nucleotides present in the miRNA. To confirm the accu-
racy of the model, a preliminary work was performed for miRNA-21 (Nhyb = 22-nts) to verify, if 
the theoretical mobility estimations of PNA‒miRNA hybrid does corresponds to the experimen-
tally obtained results. The theoretically estimated and experimentally calculated mobility of 
PNA‒miRNA-21 were found to be 1.12 × 10–4 cm2.V–1.s–1 and 1.20 × 10–4 cm2.V–1.s–1, respec-
tively. The error between the particulars was within the acceptable limits, which suggested that 
our model was appropriate to our study design. The electroosmotic mobility(µEOF)  for the CE 
running buffer (20 mM borax 20% (v/v) acetonitrile pH 9.0) was calculated experimentally as 
3.14 × 10–4 cm2.V–1.s–1 at 20 °C.    
The simulated electropherograms (Figure 12) for PNA‒miRNA hybrids differing in 
number of nucleotides of miRNAs was derived using Gaussian function by plotting f(t) corre-
sponding (t0, σ); 
                                                    (15) 
Here, t0 is the theoretically estimated migration time, σ is the peak variance correlated to 
the peak width and was obtained by fitting the experimental results with the Gaussian function 
for peak of unbound PNA probe and PNA‒miRNA hybrid, respectively. The velocity and the 
migration time were calculated using the given constant parameters: Lcap, length of the capillary 
as 80 cm; Ldet, effective length (distance between inlet and detector) as 70 cm and E, electric 
field strength as 312.5 V/cm. 
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Figure 12: Simulated electropherogram of PNA‒miRNA hybrids differing in number of nucleotides 
among the miRNAs (18‒25 nts.). Migration times of peaks shown above were estimated by using 
µEOF = 3.14 × 10−4 cm2·V−1·s−1 which was experimentally measured for CE-run buffer containing 20 mM 
borax 20% (v/v)  acetonitrile at pH 9.0. 
 
2.4.2 Universal Peptide drag tags for separation of similar length targets 
The theoretical model concludes, given that, if the number of nucleotides differs among 
the miRNAs by at the least single-base pair, the individual PNA‒miRNAs could be separated 
without the need of any modification or mobility shifters. However, for the miRNAs having 
identical number of nucleotides (similar charge to size ratios), their respective PNA‒miRNA hy-
brids would require mobility shifters, such as peptide-drag tags (earlier used in first generation 
DQAMmiR) for their resolution. Therefore, Liang modified the developed model for multiple 
miRNAs (with/without difference in number of nucleotides) by applying the effect of peptide 
drag tags on the electrophoretic mobility of the PNA‒miRNA hybrids, as for now equation (12) 
could be rewritten as; 
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                                                                (16) 
The hydrodynamic force, Ff.tag, acting on the peptide drag tag could be expressed as;  
                                      (17) 
The hydrodynamic radius of the peptide drag tag, RH,tag, could be derived by number of 
amino acid (aa) residues on the peptide drag tag [137], Ntag as: 
                                         (18) 
Substituting FE,hyb,  Ff,hyb, and Ff.tag from equations (9), (10) and (17), respectively,  in 
equation (16) and simplifying for electrophoretic mobility of PNA‒miRNA hybrids with peptide 
drag tag, µhyb+tag,: 
                            (19) 
Using final expression (equation (19)), the electrophoretic mobility calculation of PNA‒
miRNA hybrids with/without peptide drag tags can be determined. For instance, in case of 20-nts 
PNA‒miRNA hybrids, the mobility shift using different length peptide drag tags was simulated 
in the following electropherogram (Figure 13). 
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Figure 13: Simulated electropherogram for 20-nts PNA‒miRNA hybrids using peptide drag of different 
number of amino acid residues (0, 5, 10, 20 and 30 amino acid residues). Migration times of peaks shown 
above were estimated by using µEOF = 3.14 × 10–4 cm2·V−1·s−1 which was experimentally measured for the 
CE-run buffer containing 20 mM borax and 20% (v/v) acetonitrile at pH 9.0. 
 
The theoretical mobility calculated for individual PNA‒miRNA hybrids (18‒25 nts) with 
and without drag tags using equation (19) are listed in Table: 
 
Table 2: The estimated electrophoretic mobility (cm2·V–1·s–1) for PNA‒miRNA hybrids with different 
number of base pairs (18–25 nts) and different-length peptide drag tags (0, 5, 10, 15, 20, 25 and 30 aa). 
 
 0 5-aa 10-aa 15-aa 20-aa 25-aa 30-aa 
18 5.37 × 10–5 5.02 × 10–5 4.86 × 10–5 4.75 × 10–5 4.65 × 10–5 4.57 × 10–5 4.49 × 10–5 
19 6.95 × 10–5 6.40 × 10–5 6.16 × 10–5 5.99 × 10–5 5.84 × 10–5 5.72 × 10–5 5.61 × 10–5 
20 8.45 × 10–5 7.69 × 10–5 7.36 × 10–5 7.13 × 10–5 6.93 × 10–5 6.77 × 10–5 6.62 × 10–5 
21 9.88 × 10–5 8.89 × 10–5 8.48 × 10–5 8.18 × 10–5 7.94 × 10–5 7.73 × 10–5 7.55 × 10–5 
22 1.12 × 10–4 1.00 × 10–4 9.54 × 10–5 9.17 × 10–5 8.88 × 10–5 8.64 × 10–5 8.43 × 10–5 
N
hy
b 
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23 1.25 × 10–4 1.11 × 10–4 1.05 × 10–4 1.01 × 10–4 9.77 × 10–5 9.49 × 10–5 9.24 × 10–5 
24 1.38 × 10–4 1.21 × 10–4 1.15 × 10–4 1.10 × 10–4 1.06 × 10–4 1.03 × 10–4 1.00 × 10–4 
25 1.50 × 10–4 1.31 × 10–4 1.24 × 10–4 1.19 × 10–4 1.14× 10–4 1.11 × 10–4 1.08 × 10–4 
Everything taken into account, the applicability of theoretical model for multiple miR-
NAs analysis was based on two logistics: 1) for miRNAs differing in Nhyb, their respective 
PNA‒miRNA hybrids could be CE-separated without the need of peptide drag tags, 2) for miR-
NAs with identical Nhyb, their respective PNA‒miRNA hybrids could be CE-separated by attach-
ing different length peptide drag tags to complementary PNA probes. These logistics were then 
verified by performing a set of experiments for detection, separation and quantification of three 
human miRNAs simultaneously, out of which one had 22-nts (miRNA-21) and the other two had 
identical number of nucleotides, 20-nts (miRNA-378g and miRNA-147a), with 5-aa peptide drag 
tag attached to PNA probe complementary to miRNA-147a. 
 
2.4.3 Materials and Methods 
2.4.3.1 MiRNAs and complementary PNA probes. The miRNAs (miRNA-21: 5’-UAG-CUU-
AUC-AGA-CUG-AUG-UUG A-3’, miRNA- 378g: 5’- ACU-GGG-CUU-GGA-GUC-AGA-AG 
-3’, and miRNA-147a: 5’-GUG-UGU-GGA-AAU-GCU-UCU-GC-3’) were custom-synthesized 
by IDT (Coralville, IA, USA) and their  respective fluorescently labeled PNA probes (Alexa488-
O-5’-TCA-ACA-TCA-GTC-TGA-TAA-GCT-A-3’, Alexa488-O-5’-CTT-CTG-ACT-CCA-
AGC-CCA-GT-3’, and Alexa488-O-5’-GCA-GAA-GCA-TTT-CCA-CAC-AC- 3’–Gly-Ala-
Gly-Thr-Gly) were custom-synthesised by PNA Bio, Inc. (Newbury Park, CA). The other chem-
icals were obtained from Sigma-Aldrich (Oakville, ON, Canada) unless stated otherwise. 
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2.4.3.2 Hybridization Conditions. The hybridization reaction was performed in Mastercylcer 
5332 thermocycler (Eppendorf, Hamburg, Germany). Various concentrations of different miR-
NAs were incubated with constant 10 nM of their respective PNA probes in CE-running buffer. 
The temperature was increased to a denaturing 95 °C and then lowered to 60 °C at the rate of 20 
°C/minute and was held to 60°C for 30 min to allow annealing. In order to minimize miRNA 
degradation, a nuclease-free environment was maintained. 
2.4.3.3 CE-LIF.  All experiments were performed using a P/ACE MDQ CE instrument (Beck-
man-Coulter, Fullerton, CA, USA) equipped with a LIF detector. A 488 nM line of continuous 
wave solid-state laser (JDSU, Santa Rosa, CA, USA), with 1 mW effective output was utilized to 
excite fluorescently labeled probe. Fluorescence signal was detected at 520 nM wavelength. A 
bare fused-silica capillary with an outer diameter of 365 µm, an inner diameter of 50 µm, and a 
total length of 80 cm was used. The distance from the injection end of the capillary to the detec-
tor was 70 cm. Prior to each run, the capillary was flushed with 0.1M HCl, 0.1 M NaOH, deion-
ized H2O and the running buffer (20 mM borax 20% (v/v)  acetonitrile pH 9.0) for 2 minutes 
each. Samples were injected at the positive end by a pressure pulse of 0.5 psi for 5seconds; the 
volume of the injected sample was ~ 6 nL. Electrophoresis was driven by electric field of 312.5 
V/cm applied voltage and at coolant controlled temperature 20 °C. The resulting electrophero-
grams were analysed using 32 Karat software. Peak areas were divided by the corresponding mi-
gration time to compensate for the dependence of the residence time in the detector in the elec-
trophoretic velocity of analyte. 
2.4.3.4 Spectrophotometric Determination of Target and Probe Concentrations. The target 
and probe concentrations were determined by light absorption at 260 nm using the Nano-Drop 
ND-1000 spectrophotometer (Thermo-Fisher Scientific). The stock concentration of the target 
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and probe was too high to measure directly; therefore, a small sample of the each stock solution 
was serially diluted, and absorbance of each sample at 260 nm was measured 3 times. The con-
centration of each sample was determined as absorbance/εl where ε is the molar extinction coef-
ficient of the miRNAs and PNA probes at 260 nm respectively (provided by IDT/PNA Bio) and l 
is the optical path length. Using the concentrations of the serial dilutions, the original stock con-
centration was extrapolated. 
2.4.4 Result and Discussion 
2.4.4.1 Separation of three PNA‒miRNA hybrids in CE. For the proof of principle study and 
to validate the two above-stated logistics, three miRNAs were selected, such that two had identi-
cal Nhyb (20-nts; miRNA-378g and miRNA-147a) and the third one had different Nhyb from the 
former two (22-nts; miRNA-21). We prospected that since miRNA-21(23-nts) had different and 
highest Nhyb; therefore, it could be separated from other two without any modification or mobility 
shifters (peptide drag tag) and, respectively would display the lowest electrophoretic mobility. 
With concerns to the miRNAs with identical Nhyb (miRNA-378g and miRNA-147a), we made 
use of custom synthesized PNA-peptide probe (5-aa residue attached to PNA probe) complemen-
tary to miRNA-147a, in order to separate PNA‒miRNA-147a (20-nts) and PNA‒miRNA-378g 
(20-nts). The peptide tag to PNA probe complementary miRNA-147a acted as a drag and shifted 
the peak of formed PNA‒miRNA-147a (20-nts) towards left (highest electrophoretic mobility), 
away from PNA‒miRNA-378g (20-nts) resolving the two peaks. The experiments were per-
formed in CE run buffer containing 20 mM borax and 20% (v/v) acetonitrile at pH 9.0 for all 
three hybrid mixture injected at sample inlet. The experimental calculated electrophoretic mobili-
ty was compared with the theoretically estimated mobility for individual hybrids (PNA‒miRNA-
147a, -378g and -21), there was error of 29%, 26% and 6%, respectively (these errors corre-
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sponds to discrepancies in the theoretical estimation of CE-mobility to that obtained experimen-
tally) and also, in experiments, the PNA‒miRNA-147a and -378g hybrid peaks were not baseline 
separated in CE (Figure 14). This concluded that 5-amino acid peptide drag tag was not suffi-
cient to baseline separate miRNAs with identical Nhyb. 
 
Figure 14: Discrepancies between the experimental and the predicted separation of three PNA‒miRNA 
hybrids in 20 mM borax 20% (v/v) acetonitrile pH 9.0. Peak assignment: (a) excess PNA probes, (b) 
PNA‒miR-147a (20-nts, 5aa), (c) PNA‒miR-378g (20-nts), and (d) PNA‒miR-21 (22-nts). 
 
  The reduction of EOF in CE is well-known to improve resolution for poorly resolved 
peaks. One such approach to suppress EOF is by increasing ionic strength of the run buffer, µ𝐄𝐎𝐅	𝛂	 𝟏√𝐢𝐨𝐧𝐢𝐜	𝐬𝐭𝐫𝐞𝐧𝐭𝐡 [138],  hence; we optimize the ionic strength by the addition of NaCl (0, 50, 
100, and 120 mM) with the objective to baseline separate PNA‒miRNA-147a and -378g hybrids 
(Figure 15).  The resolution was calculated to track the effect after each sequential addition (Ta-
ble 3). The addition of NaCl suppressed the EOF and increased the run time. At 120 mM NaCl in 
running buffer, PNA‒miRNA-147a and -378g hybrids peak were found to be well resolved 
(Resolution: 3.1) and baseline separated. Therefore, the following CE experiments were per-
formed using 20 mM borax 120 mM NaCl 20% (v/v) acetonitrile pH 9.0 as the run buffer. 
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Figure 15: Achieving baseline separation of the three hybrids from each other by increasing the ionic 
strength of CE running buffer via addition of NaCl (0, 50, 100, 120 mM); At 20 mM borax 120 mM 
NaCl, 20% (v/v) acetonitrile, pH 9.0, the hybrids peak were well-resolved (Resolution = 3.1). Peak as-
signment: (a) excess PNA probes, (b) PNA‒miR-147a (20-nts, 5-aa), (c) PNA‒miR-378g (20-nts), and 
(d) PNA‒miR-21 (22-nts). Black, red, blue and pink trace represents the addition of 0, 50, 100, 120 mM 
NaCl in 20 mM borax 20% (v/v) acetonitrile, pH 9.0, respectively. 
 
Table 3: Resolution between the PNA‒miRNA-147a (20-nts, 5-aa) and PNA‒miRNA-378g (20-nts) at 
different NaCl concentrations in CE-running buffer. Standard deviations from mean values were obtained 
from three experiments. 
NaCl concentration (mM) in 20 mM borax 
20% (v/v) acetonitrile pH 9.0  
 
Resolution 
0 3.1 ±  0.03 
50 2.77 ± 0.01 
100 2.27 ± 0.01 
120 1.27 ± 0.02 
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2.4.4.2 Quantification of three miRNAs. The final investigation for the applicability of PNA-
facilitated DQAMmiR in miRNA multiplexing studies was to simultaneously and accurately 
quantify all three miRNAs at different concentrations. 
 2.4.4.2.1 Determination of individual (qH) and relative quantum yield (qP) of the PNA 
probes complementary to three miRNAs.  For accurate quantification of miRNAs, two consid-
erations were taken into account; 1) individual quantum yield, qH of PNA-miRNA hybrids 
probes with respect to their unbound probes and, 2) relative quantum yield, qP of the probes (sig-
nifies the potential difference of quantum yields between the individual probes). The qH was de-
termined following the previously described expression for a single miRNA analysis. For deter-
mination of qP, the fluorescence intensities of individual probe were normalized by calculating 
its relative quantum yield to PNA probe complementary to miRNA-21 (used as the normaliza-
tion factor) as shown in Figure 16. The Table 4 list the calculated qH and qP values:  
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Figure 16: CE-LIF-facilitated determination of qH and qP for individual PNA probes using rhodamine as 
internal standard. (A) qH for PNA probe complementary to miR-21; black trace with no target, red trace 
with target. (B) qH for PNA probe complementary to miR-378g; black trace with no target, red trace with 
target. (C) qH for PNA probe complementary to miR-147a; black trace with no target, red trace with tar-
get. (D) qP determination with respect to PNA probe for miR-21; PNA probes complementary to miR-21, 
378g and 147a are represented by black trace, red and blue trace respectively.  
 
Table 4: Quantum yields of PNA‒miRNA hybrids (qH) to their unbound PNA probes and Relative quan-
tum yields of the PNA probes (qP) to the PNA probe corresponding/complementary to miR-21 for signal 
normalization. Standard deviations from mean values were obtained from three experiments. 
 
PNA probe complementary to  
miRNA-147a miRNA-378 g miRNA-21 
qH  0.26 ± 0.01 0.34 ± 0.05 0.27 ± 0.02 
qP  0.82 ± 0.04 0.78 ± 0.04 1 
 
 48 
 
2.4.4.2.2 Expression for quantification of multiple miRNAs using PNA-facilitated DQAM-
miR. The unknown concentration of the i-th miRNA, [miRNA]i, could be expressed through the 
area of its respective hybrid peak, AH,i, using the unknown coefficient a, and known quantum 
yields qHi and qPi: 
                                                                                                          (20) 
          The known concentration of the i-th probe, [P]0,I, could be expressed through two peak ar-
eas, APi and AHi , corresponding  to unbound PNA probe and miRNA-bound probe, respectively, 
with the same coefficient a  and the known quantum yield qHi  and qPi: 
                                                 (21) 
                                                        (22) 
Similarly, for N, number of probes and hybrids,  
                                          (23) 
For the above expression, the corresponding peak area for individual hybrid (AHi) could 
be determined experimentally and, the unbound PNA probe came out in form of overlapped 
peaks due to similar mobilities and therefore, their cumulative peak area (APi) could be expressed 
as AP =  and below equation can be obtained: 
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                                             (24) 
Here, a can be expressed as; 
                                                                         (25) 
By substituting a from equation (25) to equation (24), the final equation (26) was derived 
to quantitate i-th miRNA from a single electropherogram without plotting a calibration curve 
                                                 (26) 
            In final expression (equation (26)), [P]0i is the total concentration of the i-th PNA probe 
(composed of the unbound and the target-bound probe), AH i is the area corresponding to the i-th 
hybrid, AP is the cumulative area of the unbound probes, qPi is a relative quantum yield of the i-th 
PNA probe to normalize the quantum yield differences between the probes, and qHi is the relative 
quantum yield of the i-th hybrid with respect to that of the unbound probe. Both qPi and qHi were 
determined in separate experiments. 
  
2.4.4.2.3 5-point quantification for multiple miRNAs. The different concentration miRNAs 
(500, 250, 125, 62.5, and 31.25 pM) were incubated with constant concentration of their respec-
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tive PNA/PNA-peptide probes (10 nM) in the same vial for hybridization and thereafter, the 
formed hybrids were CE analysed (Figure 17). 
 
         
Figure 17: A) CE-Electropherograms of PNA-facilitated DQAMmiR measurements. Peak assignment: 
(a) excess PNA probes, (b) PNA‒miR-147a (20-nts, 5-aa), (c) PNA‒miR-378g (20-nts), (d) PNA‒miR-
21 (22-nts). Electropherograms i–v correspond to target concentrations of 500, 250, 125, 62.5, and 31.5 
pM, respectively. B) Quantitation plot between PNA-facilitated DQAMmiR measured concentrations and 
spectroscopically determined concentration at 260 nm  for three miRNAs simultaneously. miRNA-21, 
miRNA-147a, and miRNA-378g, are represented by black rectangles, red circles, and blue triangles, 
respectively. The dashed line (y = x) represents a line corresponding to 100% recovery. Error bars 
represent standard deviation from mean values obtained from three experiments. 
 
The accuracy of the assay was determined by comparing the PNA-facilitated DQAMmiR 
concentration to the spectroscopically determined miRNA concentrations at 260 nm. A recovery 
between 90‒110% and relative standard deviation (RSD) of <15% was observed for all three 
miRNAs analysed simultaneously (Table 5). In addition, we determined limit of detection 
(LOD) for our assay as 14 pM by studying signal to noise ratio (S/N) of the hybrid peaks.  
(A) (B) 
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Table 5: Quantification results obtained from PNA-facilitated DQAMmiR for three miRNAs (miRNA-
147a, miRNA-378g and miRNA-21) corresponding to their actual concentrations as determined spectro-
scopically at 260 nm. Standard deviations and recovery from mean values were obtained from three ex-
periments. 
Actual miR-
NA Concen-
tration (pM) 
 
DQAMmiR-Measured miRNA Concentration (pM, Mean ± Standard Deviation) & % 
Recovery 
miR-21 miR-147a miR-378g 
 Concentration 
(in pM) 
% Recovery Concentration 
(in pM) 
% Recovery Concentration 
(in pM) 
% Recovery 
500 461 ± 28 92 538 ± 11 107 483 ± 17 97 
250 229 ± 25 91 287 ± 30 114 240 ± 19 96 
125 128 ± 14 102 138 ± 4 110 118 ± 6 94 
62.5 59 ± 6 94 69 ± 5 110 60 ± 15 96 
31.25 29 ± 4 93 33 ± 2 101 33 ± 2 106 
 
2.4.5 Conclusion 
Here, we introduced and developed the second generation DQAMmiR which is, in prin-
ciple, more simpler and robust than first generation DQAMmiR, as it omits the addition of exter-
nal mobility modifier (e.g., SSB) to separate the excess unbound hybridization probes from the 
formed hybrids.  The assay employs the use of PNAs, which are neutral polymer, capable of hy-
bridizing with the miRNAs at accelerated rate (due to lack of repulsion) and as being charge-
neutral render electrophoretic mobility different from the partial-negatively charged PNA‒
miRNA hybrids (due to negative charge on  miRNAs) separating the excess unbound PNA 
probes and the formed PNA‒miRNA hybrids. Yet, PNA-facilitated DQAMmiR, like first gen-
eration, requires peptide drag tags and optimal CE conditions for the separation of similar mobil-
ity hybrids (miRNAs having identical Nhyb). Following this, we simultaneously quantified three 
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miRNAs with recovery in between 90–110%, RSD <15% and LOD  ̃14 pM using commercial 
CE setting. The accuracy, precision and sensitivity of our assay suggested its potential use for 
cost-effective analysis of known clinically relevant miRNAs in basic laboratory settings. 
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Chapter Three 
VALIDATION OF PNA-FACILITATED DQAMmiR IN 
CRUDE CELL LYSATE 
 
3.1 Background 
MiRNAs have well-proven their significance as a promising diagnostic and prognostic 
cancer biomarkers. Despite of their exceptional potential, the clinical quantification of miRNAs 
is technically challenging due to their low abundance, small size and high sequence homology. 
Though there are currently numerous established methods that dissert their clinical potential to 
be sensitive and specific, such as well-known gold standard RT-qPCR, Nanostring, deep se-
quencing, etc.; however, with regards to their respective shortcomings, the demand to develop a 
simple, robust and multiplexable quantitative miRNA detection assay still persists. Moreover, 
most of the existing techniques essentially require sample processing and RNA extraction, which 
is, in turn challenging and typically rate-limiting. The available commercial and in-house rea-
gents commonly used for RNA isolation are more or less prone to variability in quantification 
data (decreasing the reliability of the assay) and also, there no standardization/normalization pro-
cedure to follow for the same. In addition, these reagents overall increases the assay cost and are 
not easily feasible [74, 139, 140].  
Our lab had introduced PNA-facilitated DQAMmiR which is advantageous, importantly, 
for its direct approach, i.e., does not require RNA extraction/amplification. This reduces the ex-
traction- and amplification-based biases and facilitates reliable absolute quantification of multi-
ple miRNAs simultaneously. Briefly, it is a hybridization assay which involves the use of un-
 54 
 
charged PNA probes, in excess (to reduce the hybridization time) to hybridize with the comple-
mentary  miRNAs in solution and subsequent separation of the formed hybrids from each other 
(using peptide-drags) and from excess probes (charge difference) in commercial CE-LIF settings. 
The absolute quantification of individual miRNA is achieved using mathematically derived ex-
pression by equating the experimentally determined variables. The earlier work demonstrated the 
assay potential of being sensitive, accurate (RSD <10%) and robust for relatively cost-effective 
miRNAs analysis. In addition, CE-LIF provides sensitive and specific analysis of trace biomole-
cules in complex sample matrices such as cell lysates, tissues and various biofluids [92, 93]. Pre-
viously, the first generation DQAMmiR had proved its robustness in analysing miRNAs, irre-
spective of sample matrices, by performing comparative studies for single miRNA in pure buffer 
and crude cell lysate. 
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide 
and it is the fifth leading cause of cancer-related death [141]. However, the most important clini-
cal challenge in its diagnosis is to distinguish men who have potentially lethal form of PCa from 
those with an indolent (slow-growing) disease [142]. Presently, the stratification of PCa patient is 
guided by the PSA (prostate specific antigen) kinetics, clinical stage, and Gleason score (tumor 
grade). Though these parameters are helpful, these have limitations in detecting cases, predicting 
disease outcomes and in guiding clinical management. Hence, new biomarkers are pressingly 
needed to overcome the limitation of existing diagnostic and prognostic approaches. Studies re-
vealed the dysregulated miRNAs expressions in PCa and their potential of being employed as 
biomarkers for diagnosis [143]. 
Here we demonstrate the multiplexed quantification of endogenously-present miRNAs 
directly from crude PCa cell-lysate without isolating RNA, using PNA-facilitated DQAMmiR. 
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For this work, we selected two known prostate cancer specific dysregulated miRNAs; miRNA- 
20b and miRNA-100. MiR-20b has reported to be strongly overexpressed in cancerous tissues 
compared to the normal prostate tissues; it acts as oncogene and promotes cellular proliferation 
and migration by directly regulating phosphatase and tensin homolog in prostate cancer [144]. 
MiRNA-100 act as tumor-suppressor, downregulation of which enhances migration, invasion 
and transition properties in PCa cells [145]. The use of appropriate lysis buffer made it possible 
to liberate miRNAs from the cells and from the carrier protein for the accurate analysis. In this 
respect, an assay validation procedure was designed to observe the CE pattern in presence of 
pure buffer and crude cell lysate. As a part of which, we employed standard addition approach to 
determine the miRNAs concentration in prostate cancer cell by adding known concentrations of 
respective prostate cancer-related miRNAs in cell lysate and pure buffer and generating the re-
spective standard addition plots. The accurate miRNA detection and quantification in PCa cell 
line would get our assay a step closer to its clinical implementation to actual patient-derived 
samples in diagnostic settings. 
 
3.2 Material and Methods 
3.2.1 MiRNAs and complementary PNA probe. The miRNAs (miR-20b: 5’- CAA-AGU-
GCU-CAU-AGU-GCA-GGU-AG -3’, miR-100: 5’- AAC-CCG-UAG-AUC-CGA-ACU-UGU-
G-3’ ) was custom-synthesized by IDT (Coralville, IA, USA) and their respective fluorescently 
labeled PNA probe (Alexa 647-O-O-5’- CTA-CCT-GCA-CTA-TGA-GCA-CTT-TG -3’, Alexa 
647-O-O-5’- CAC-AAG-TTC-GGA-TCT-ACG-GGT-T -3`–Gly-Thr-Gly-Ala-Gly ) was cus-
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tom-synthesised by Panagene, Inc. (Yuseong-gu, Daejeon, Korea).The other chemicals were ob-
tained from Sigma-Aldrich (Oakville, ON, Canada) unless stated otherwise.  
3.2.2 Hybridization Conditions. The hybridization reaction was performed in Mastercylcer 
5332 thermocycler (Eppendorf, Hamburg, Germany). Various concentrations of different miR-
NAs were incubated with constant 10 nM of their respective PNA probes in CE-running buffer 
and cell lysate. The temperature was increased to a denaturing 95 °C and then lowered to 60 °C 
at the rate of 20 °C/minute and was held to 60°C for 30 min to allow annealing. In order to min-
imize miRNA degradation, a nuclease-free environment was maintained. 
3.2.3 CE-LIF. All experiments were performed using a P/ACE MDQ CE instrument (Beckman-
Coulter, Fullerton, CA, USA) equipped with a LIF detector. A 641 nm line of continuous wave 
solid-state laser (JDSU, Santa Rosa, CA, USA), with 1 mW effective output was utilized to ex-
cite fluorescently labeled probes. Fluorescence signal was detected at 679 nm wavelength. A 
bare fused-silica capillary with an outer diameter of 365 µm, an inner diameter of 75 µm, and a 
total length of 80 cm was used. The distance from the injection end of the capillary to the detec-
tor was 70 cm. Prior to each run, the capillary was flushed with 0.1M HCl, 0.1 M NaOH, deion-
ized H2O and the running buffer (20 mM borax 20% (v/v)  acetonitrile pH 9.0) for 2 minutes 
each. Samples were injected at the positive end by a pressure pulse of 0.5 psi for 5seconds; the 
volume of the injected sample was ~ 6 nL. Electrophoresis was driven by electric field of 312.5 
V/cm applied voltage and at coolant controlled temperature 20 °C. The resulting electrophero-
grams were analysed using 32 Karat software. Peak areas were divided by the corresponding mi-
gration time to compensate for the dependence of the residence time in the detector in the elec-
trophoretic velocity of analyte. 
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3.2.4 Spectrophotometric Determination of Target and Probe Concentrations. The target 
and probe concentrations were determined by light absorption at 260 nm using the Nano-Drop 
ND-1000 spectrophotometer (Thermo-Fisher Scientific). The stock concentration of the target 
and probe was too high to measure directly; therefore, a small sample of the each stock solution 
was serially diluted, and absorbance of each sample at 260 nm was measured 3 times. The con-
centration of each sample was determined as absorbance/εl where ε is the molar extinction coef-
ficient of the miRNAs and PNA probes at 260 nm respectively (provided by IDT/PNA Bio) and l 
is the optical path length. Using the concentrations of the serial dilutions, the original stock con-
centration was extrapolated. 
3.2.5 Prostate cancer cell culture and lysis. DU145 cells were obtained by Stanley K. Liu lab. 
The cell were grown in DMEM culture medium supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin at 37 °C in a humidified environment of 5% CO2, in air. Cells were har-
vested at 50-70% confluency using trysin/EDTA (0.25%/0.5 mM) and centrifuged at 5000 rpm 
for 5 min to form pellet. The washing of the formed pellets was done twice with 1XPBS. Subse-
quently, the cells were counted in hemocytometer. The cells were lysed in CE-running buffer 
containing 2% of SDS (sodium docyl sulphate). The cell lysate were aliquoted and stored at -80 
°C. 
 
3.3 Result and Discussion 
 We aimed to scale our assay to simultaneously and quantitatively analyse two PCa- 
dysregulated miRNAs in crude cell lysate without any RNA extraction. Since, a single miRNA 
biomarker might not be sufficient to study the state of the disease, hence, we analysed two PCa 
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dysregulated miRNAs (miR-20b, oncogene and miR-100, tumor-suppressor gene) having 23-and 
22-nts, respectively. Similarly, two complementary PNA probes were employed with one conju-
gated with 5-aa peptide drag (to ensure sufficient separation of the two formed hybrids). Broadly, 
the work had two stages; 1) PCa cell lysis, and 2) miRNAs analysis by PNA-facilitated DQAM-
miR.  
3.3.1 Cell Lysis 
  MiRNAs display exceptional stability in physiological environment; however, miRNA 
is rarely found in free-state and is mostly either protein-bound (with RNA-binding protein, HDL) 
or enclosed in microvesicles and apoptotic bodies [15]. We performed alkaline lysis using high 
concentration (2%) of SDS in the incubation buffer (20 mM borax 20% (v/v) acetonitrile pH 
9.0); to cause disruption of cell walls and denaturation of all protein associated with miRNAs for 
their efficient and complete release in cell-lysate. SDS is a strong anionic detergent and one of 
the most commonly used surfactant for cell-lysis in biochemical assays for rapid cell lysis on the 
order of seconds without the need of any special equipment [146]. 
3.3.2 Method Validation in presence of cell lysate  
PNA as hybridization probes are well-known to be stable in degrading cellular environ-
ment, in comparison to usual DNA/LNA probe, due to its unnatural backbone (resistant to nucle-
ase degradation). Moreover, PNA‒RNA duplexes have reported to be more intact in degrading 
cellular environment than DNA‒RNA or RNA‒RNA duplexes [116, 147]. To perform quantita-
tive analysis of miRNAs in PCa derived crude cell lysate, the respective PNA probes were added 
to the lysate at constant concentration and varying the concentrations of spike-in miRNAs fol-
lowing the earlier used hybridization protocol. In addition, similar PNA probe mixture and miR-
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NA concentrations were also spiked-in pure buffer, in order to notice, if any, matrix effects. The 
hybridized sample was then injected to the capillary and CE-LIF analysed.  
 In our study, clinical validity of the method was attended taking into account the following crite-
ria: ability to detect endogenous miRNA, accuracy, precision, linearity, limit of detection (LOD) 
and limit of quantification (LOQ). Furthermore, we performed cross-reactivity analysis of the 
probe in the presence of non-specific/cross miRNAs. 
3.3.2.1 Detection of endogenous miRNA. To check the sensitivity of our assay in detecting en-
dogenous miRNA, the respective probes (complementary to miRNA-20b and miR-100) were 
incubated in PCa cell lysate (1 million/ml), which was followed by CE analysis. With given con-
ditions, we were able to detect one hybrid peak (electrophoretic mobility similar to PNA‒miR-
20). Further to identity the peak, the two miRNAs were subsequently spiked-in (at low concen-
tration) to probes-cell lysate solution. From the result shown in Figure 19, Table 6 we hypno-
tised the hybrid peak to be of miRNA-20. This indicated the potential ability of our assay to de-
tect endogenous upregulated miRNA-20 without RNA extraction or miRNA amplification using 
commercial CE setting. 
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Figure 18: Detection of endogenous miRNA in PCa cell lysate (1 million/ml). (a) CE run for 1 nM PNA 
probes in cell lysate with no miRNA spiking; (b) CE run for 1 nM PNA probe mixture with spiked 100 
pM miRNA-100; and (c) CE run for 1 nM PNA probe mixture with spiked 100 pM miRNA-100 and 100 
pM miRNA-20.  
 
Table 6: Detection and quantification of endogenous miRNA in PCa cell lysate (1 million/ml) by doing 
spike-in analysis. (a) 1 nM PNA probe mixture in cell lysate with no miRNA spiking (b) CE run for 1 nM 
PNA probe mixture with spiked 100 pM miRNA-100 (c) 1 nM PNA probe mixture with spiked 100 pM 
miRNA-100 and 100 pM miRNA-20. The experiment was done in duplicates 
  Spiked-in Concentra-
tion (in pM) 
Calculated Concen-
tration  (in pM) 
(a) miRNA-100 
miRNA-20 
0 
0 
0 
>LOD, <LOQ 
(b) miRNA-100 
miRNA-20 
100 
0 
97.8 
>LOD, <LOQ 
(c)  miRNA-100 
miRNA-20 
100 
100 
95.4 
154.5 
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3.3.2.3 Accuracy. The obtained CE results were used to quantify the five different spike-in con-
centrations of the both miRNAs. The concentrations of the miRNAs were determined using (ear-
lier derived) following equation: 
 
      Here, [P]0i is the total concentration of the i-th PNA probe (composed of the hybrid and the 
excess probe), AHi is the area corresponding to the i-th hybrid, AP is the cumulative area of the 
unbound probes, qPi is a relative quantum yield of the i-th PNA probe to normalize the quantum 
yield differences between the probes, and qHi is the relative quantum yield of the i-th hybrid with 
respect to that of the unbound probe. Both qPi and qHi were determined in separate experiments 
(Figure 19) and listed in Table 6. 
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 (C) q
P
 determination with respect to PNA probe for miR-20; PNA probes for miR-20 and 100 are 
represented by black trace and red trace respectively. 
 
 
 
Table 7: Quantum yields of PNA‒miRNA hybrids (qH) to their unbound PNA probes and relative quan-
tum yields of the PNA probes (qP) to the PNA probe corresponding/complementary to miR-20 for signal 
normalization. Standard deviations from mean values were obtained from three experiments. 
 
 
PNA probe complementary to  
miRNA-20a miRNA-100 
q
H
  0.26 ± 0.01 0.28 ± 0.03 
q
P
  0.88 ± 0.02 1 
 
 
Figure 19: CE-LIF-facilitated determination of q
H 
and q
P
 for individual red laser excited PNA probes 
using Alexa-647 as internal standard. (A) q
H
 for 
PNA probe complementary to miR-20; black trace 
with no target, red trace with target. (B) q
H
 for 
PNA probe complementary to miR-100; black 
trace with no target, red trace with target. 
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Various concentrations of miRNAs (0, 0.125, 0.25, 0.5, 1, and 2 nM) were incubated with 
the constant concentration of PNA probes in pure buffer and in cell lysate. The formed hybrid 
were analysed in CE; and their respective concentrations were determined using earlier derived 
equation (Figure 20). The percentage recovery for all the concentrations for both miRNAs was 
between 90–113% and percentage error <15%, irrespective of matrix (Table 7).  
 
Table 8: Quantification results obtained from PNA-facilitated DQAMmiR for two miRNAs (miRNA-20b 
and miRNA-100) corresponding to their actual concentrations as determined spectroscopically at 260 nm 
in presence of pure buffer and cell lysate. Standard deviations and percentage recovery (%) from mean 
values were obtained from three experiments. 
 
Actual miRNA 
Concentration 
(nM) 
DQAMmiR-Measured miRNA Concentration (nM), Mean ± Standard Deviation) and % Recovery 
Pure buffer Cell lysate 
miR-20 miR-100 miR-20 miR-100 
Concentration 
(nM) 
% Recovery Concentration 
(nM) 
% Recovery Concentration 
(nM) 
% Recovery Concentration 
(nM) 
% Recov-
ery 
2 1.93 ± 0.07 96 1.89± 0.07 94 2.2 ± 0.05 107 2.17 ± 0.03 108 
1 1.1 ± 0.04 110 1.01 ± 0.05 101 1.02 ± 0.03 98 0.97 ± 0.01 97 
0.5 0.52 ± 0.01 104 0.49 ± 0.03 98 0.54 ± 0.02 98 0.51 ± 0.01 101 
0.25 0.24 ± 0.01 96 0.23 ± 0.01 92 0.29 ± 0.01 97 0.26 ± 0.01 102 
0.125 0.135 ± 0.005 107 0.138 ± 0.01 107 0.164 ± 0.01 93 0.142 ± 0.01 113 
0 0 0 0 0 0.039± 0.005 - <LOD - 
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Figure 20: Spike-in recovery/ miRNA detection in CE in (A) pure buffer, and (C) cell lysate at different 
spiked-in concentrations. Electropherograms 1-6 correspond to miRNA concentrations of 0, 0.125, 0.25, 
0.5, 1, and 2 nM, respectively. The 5- point calibration plot for different concentrations of miRNAs in (B) 
pure buffer, and (D) cell lysate. Error bars represents the standard deviations obtained from the mean of 
triplicate runs. Peak assignments: (a) unbound probe, (b) PNA‒miR-100 (22-nts‒5aa), and (c) PNA‒miR-
20 (23-nts). 
 
(A) (B) 
(D) (C) 
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2.2.3 Precision.  Precision governs the quality of data, hence, good precision, as repeatability 
and inter-day precision is required to demonstrate the performance efficiency of the method. Re-
peatability was obtained from the analysis, during same day, of three replicates of three different 
concentrations for individual miRNA and coefficient of variation (CV) of all cases was obtained. 
The inter-day precision was determined by measuring standard curve (in triplicates) on two dif-
ferent days at low (0.125 nM), medium (0.5 nM) and high (2 nM) miRNA concentrations and 
hence, coefficient of variation was obtained. The CV was found to be <15% (Table 8) proving 
our assay to be precise.  
 
Table 9: Coefficient of variation (%) for miRNAs in pure buffer and cell lysate (1 million/ml) for low 
(0.125 nM), medium (0.5 nM) and high (2 nM) miRNA concentration. 
Actual miRNA Con-
centration (nM) 
Coefficient of Variation (%) 
Pure buffer Cell lysate  
miR-20 miR-100 miR-20 miR-100 
2  3.63 2.2 2.32 1.6 
0.5  2.73 6.21 5.83 6.94 
0.125  3.98 6.8 6.18 7.69 
 
 
3.3.2.4 Linearity. The 5-point standard addition curve was prepared by plotting five different 
spectroscopically determined and PNA-facilitated DQAMmiR calculated spiked-in concentra-
tions of the individual miRNAs in the cell lysate. Linearity of the curve for each miRNA was 
verified by the coefficient of determination (R2 > 0.99) and the coefficient of variation between 
the response factors (CV > 15%). 
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3.2.2.5 Limit of detection and Limit of quantification. The minimum concentration that pro-
vided a signal to noise ratio equal to 3 for both miRNAs was denoted limit of detection for our 
assay and the limit of quantification was set as the minimum concentration that gave signal to 
noise ratio equal to 10, whose average should not deviate beyond d ± 20% of the known actual 
concentration. The LOD and LOQ for our assay was measured by linear regression analysis and 
plotting signal to noise ratio plot between different concentration of both PNA‒miRNAs in pure 
buffer and in cell lysate (Figure 21). The LOD and LOQ for respective miRNAs in presence of 
pure buffer and cell lysate are shown in Table 9. 
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Figure 21: Signal to noise ratio plot in pure buffer for (A) PNA‒miR-20 (23-nts), and (B) PNA‒miR-100 
(22-nts-5-aa); and in the presence of cell lysate for (C) PNA‒miR-20 (23-nts), and (D) PNA‒miR-100 
(22-nts-5-aa) at different concentration. Error bars represents the standard deviations obtained in triplicate 
runs. 
 
Table 10: Limit of detection and limit of quantification for individual miRNA obtained in presence of 
pure buffer and cell lysate 
 
Pure buffer Cell lysate 
miR-20  miR-100 miR-20  miR-100 
LOD (in pM) 20 16 29 24 
LOQ (in pM) 59 54 63 50 
 
(A) (B) 
(C) (D) 
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3.3.2.6 Cross-reactivity of the probe.  In the physiological samples, there is not just the target 
miRNAs; rather multiple miRNAs with high sequence homology are present. With any miRNA 
hybridization assay, there is a wide variance in melting temperatures of the different hybrids. 
Each probe has a specific temperature at which specific miRNA binding occurs while non-
specific binding does not. To test the specific behaviour of PNA-facilitated DQAMmiR, we in-
cubated PNA probe complementary to miR-20b with miR-100 and vice-versa (Figure 22). The 
results justified that even at high probe and target concentration (ensures accelerated hybridiza-
tion); neither of PNA probes showed any cross-reactivity to their non-specific miRNAs. 
 
 
Figure 22: Cross-reactivity analysis for PNA probes; (A) CE run for10 nM PNA complementary to miR-
20b incubated with: no target (black trace); 1 nM specific miR-20b (blue trace) ;and 1 nM non-specific 
miR-100 (red trace). (B) CE run for 10 nM PNA complementary to miR-100 incubated with: no target 
(black trace); 1 nM specific miR-100 (blue trace); and 1 nM non-specific miR-20b (red trace). Either of 
PNA probes shows no hybrid peak with non-complementary targets. Peak assignments: (a) PNA‒
miRNA-20 (23-nts), and (b) PNA‒miRNA-100 (22-nts-5aa). 
(A) (B) 
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3.4 Conclusion  
Here, we aimed to validate the feasibility of PNA-facilitated DQAMmiR in the presence 
of crude cell lysate derived from prostate cancer cell lines. The method fulfilled the general vali-
dation criteria for analytical technique including suitable level of linearity, low limit of detection 
and limit of quantification, good repeatability and reproducibility, and high recovery and accura-
cy; irrespective of sample matrix (pure buffer/cell lysate). Furthermore, with given conditions, 
we were able to detect an endogenous target (miRNA-20), which reported to be upregulated in 
prostate cancer, without any extraction and/or amplification. The success of the cell-lysate vali-
dation study is a milestone to scale our method to the clinical studies on patient-derived sample 
for miRNAs analysis. 
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LIMITATIONS 
Though PNA-facilitated DQAMmiR is an improvement of our lab-developed first generation 
DQAMmiR, in the respect that this particular assay does not require any external mobility shifter 
(e.g., SSB) to resolve miRNA‒bound probes from the excess unbound probes, owing to the neu-
tral framework of PNA probes in comparison to partial negatively-charged PNA‒miRNA hy-
brids; however, the particular also have its drawbacks. Firstly, the synthesis PNAs by itself is 
relatively more expensive than usual DNA/LNA probes, which overall increases the assay-cost. 
Secondly, being built on uncharged peptide chain (N-amino-ethyl-glycine units), PNA poses not 
only solubility problem (which affects its delivery into the solution), but also tends to adhere to 
the walls of capillary (during CE), which in turn leads to excess unbound PNA probes not reach-
ing the detector. We tried to overcome this, by using PNA probes with O-linkers and addition of 
organic solvent (20% v/v acetonitrile) to all the working solutions/buffers. Thirdly and more crit-
ically, the presence of unnatural backbone, though this protects the PNA‒miRNA hybrids from 
the enzymatic degradation, but the (non-ribose phosphate) backbone flexibility of PNA creates 
difficulty in the theoretical prediction of the PNA‒miRNA hybrids mobility. The latter is im-
portant in multiplexing studies to design PNA/PNA‒peptide probes. Our lab is still working to 
develop a more robust theoretical model to predict the hybrids mobility.  Finally, the same inher-
ent limitation of low sensitivity to detect very low abundance miRNAs in the physiological sam-
ple, similar to first generation DQAMmiR still persists. Ongoing work continues to develop an 
in-house CE detection set-up that potentially will reduce the LOD down to few hundreds copies 
of miRNAs, in practice.  
 CONCLUSION AND FUTURE WORK 
The accurate quantification of miRNAs expression profile is crucial for understanding their 
prominent role in gene regulation and indeed to extend their clinical application as disease bi-
omarkers. There are only a few methods which satisfy the criteria of accurate and reliable quanti-
tation and facilitate multiplexing.  One of such approaches was previously being developed by 
our lab is direct quantitative analysis of multiple miRNAs (DQAMmiR) by gel-free capillary 
electrophoresis. I worked in the process of developing the second the generation DQAMmiR, 
which is simpler and more robust than the first generation, in regards, of omitting the addition of 
external agents (SSB) to separate the target-bound probes from the target-unbound probes, by the 
incorporation of electrically neutral polymer, PNAs, as hybridization probes. Yet, for separating 
the PNA‒miRNA hybrids from each other we were still required to conjugate peptide drag tags 
on PNA probes. Our approach and logistics were confirmed by the proof-of-principle study: 
firstly, to see separation between the hybrid and excess probe using a single miRNA and second-
ly, using peptide drag to simultaneously quantify three different targets with appreciable accura-
cy and precision. Later, my study also involved the validation of our developed method in the 
prostate cancer-derived cell lysate to show good linearity, accuracy and precision, irrespective of 
sample matrix. In addition, our assay was able to detect endogenous PCa-upregulated miRNA 
without performing any extraction and/or miRNA amplification. 
Our lab is currently working to take the assay to its next level of clinical validation to analyze 
cancer-deregulated miRNAs at lower LOD and LOQ in actual patient-derived samples (tissues 
and biofluids such as, urine, blood, etc) accurately, specifically and reproducibly.  
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